Literature DB >> 8467609

Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus.

E Röther1, B Lang, R Coldewey, K Hartung, H H Peter.   

Abstract

In order to investigate, if complement levels can be used as an indicator of clinical activity in systemic lupus erythematosus (SLE), levels of C3, C4, CH50, and C3d were measured in 79 patients, 41 with inactive, 31 with moderately active and 7 with severely active disease. Our study shows that C3d, and particularly the C3d/C3 ratio, provide sensitive markers for disease activity in SLE. Since C3d is a direct measurement of complement turnover, it reflects complement activation better than C3, C4 and CH50.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8467609     DOI： 10.1007/bf02231555

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  24 in total

1.  Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.

Authors:  L H Perrin; P H Lambert; P A Miescher
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

2.  Complement activation during hemodialysis. Comparison of polysulfone and cuprophan membranes.

Authors:  S Stannat; J Bahlmann; D Kiessling; K M Koch; H Deicher; H H Peter
Journal:  Contrib Nephrol       Date:  1985       Impact factor: 1.580

3.  Measurement of the complement C3 breakdown product C3d by rocket immunoelectrophoresis.

Authors:  B E Bourke; I K Moss; R N Maini
Journal:  J Immunol Methods       Date:  1982       Impact factor: 2.303

4.  Effectiveness of testing for anti-DNA and the complement components iC3b, Bb, and C4 in the assessment of activity of systemic lupus erythematosus.

Authors:  J D Clough; R K Chang
Journal:  J Clin Lab Anal       Date:  1990       Impact factor: 2.352

5.  Association of class I, II, and III MHC gene products with systemic lupus erythematosus. Results of a Central European multicenter study.

Authors:  K Hartung; A Fontana; M Klar; H Krippner; K Jörgens; B Lang; H H Peter; W J Pichler; D Schendel; M Robin-Winn
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

6.  The clinical significance of iC3b neoantigen expression in plasma from patients with systemic lupus erythematosus.

Authors:  N Negoro; M Okamura; T Takeda; S Koda; K Amatsu; T Inoue; J G Curd; Y Kanayama
Journal:  Arthritis Rheum       Date:  1989-10

7.  The C1q binding assay in systemic lupus erythematosus: discordance with disease activity.

Authors:  R D Inman; J K Fong; B A Pussell; P J Ryan; G R Hughes
Journal:  Arthritis Rheum       Date:  1980-11

8.  Double-decker rocket immunoelectrophoresis for direct quantitation of complement C3 split products with C3d specificities in plasma.

Authors:  I Brandslund; H C Siersted; S E Svehag; B Teisner
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

9.  Correlation of C3d fixing circulating immune complexes with disease activity and clinical parameters in patients with systemic lupus erythematosus.

Authors:  K Sekita; T Doi; E Muso; H Yoshida; K Kanatsu; Y Hamashima
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

10.  Multiple serologic reactions and their relationship to clinical activity in systemic lupus erythematosus.

Authors:  D A Isenberg; Y Shoenfeld; R S Schwartz
Journal:  Arthritis Rheum       Date:  1984-02
View more
  10 in total

1.  Complement receptor 2 is expressed in neural progenitor cells and regulates adult hippocampal neurogenesis.

Authors:  Maiko Moriyama; Takeshi Fukuhara; Markus Britschgi; Yingbo He; Ramya Narasimhan; Saul Villeda; Hector Molina; Brigitte T Huber; Mike Holers; Tony Wyss-Coray
Journal:  J Neurosci       Date:  2011-03-16       Impact factor: 6.167

2.  Antineutrophil cytoplasmic antibodies (ANCA) in rheumatoid arthritis: a prospective study.

Authors:  E Röther; T Schochat; H H Peter
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

Review 3.  Clinical utility of complement assessment.

Authors:  A E Ahmed; J B Peter
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

4.  Occurrence of C-reactive protein in cryoglobulins.

Authors:  S M Weiner; V Prasauskas; D Lebrecht; S Weber; H H Peter; P Vaith
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

5.  Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET.

Authors:  S M Weiner; A Otte; M Schumacher; R Klein; J Gutfleisch; I Brink; P Otto; E U Nitzsche; E Moser; H H Peter
Journal:  Ann Rheum Dis       Date:  2000-05       Impact factor: 19.103

6.  Precursor frequencies for DNA-specific B lymphocytes in patients with systemic lupus erythematosus (SLE).

Authors:  J Schwab; A Lukowsky; H D Volk; H H Peter; I Melchers
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

7.  Detection and functional resolution of soluble immune complexes by an FcγR reporter cell panel.

Authors:  Haizhang Chen; Andrea Maul-Pavicic; Martin Holzer; Magdalena Huber; Ulrich Salzer; Nina Chevalier; Reinhard E Voll; Hartmut Hengel; Philipp Kolb
Journal:  EMBO Mol Med       Date:  2021-11-29       Impact factor: 12.137

8.  Systemic complement activation levels in Stargardt disease.

Authors:  Patty P A Dhooge; Esmee H Runhart; Catherina H Z Li; Corrie M de Kat Angelino; Carel B Hoyng; Renate G van der Molen; Anneke I den Hollander
Journal:  PLoS One       Date:  2021-06-25       Impact factor: 3.240

9.  Systemic complement activation in central serous chorioretinopathy.

Authors:  Elon H C van Dijk; Roula Tsonaka; Ngaisah Klar-Mohamad; Diana Wouters; Aiko P J de Vries; Eiko K de Jong; Cees van Kooten; Camiel J F Boon
Journal:  PLoS One       Date:  2017-07-03       Impact factor: 3.240

10.  The C3dg Fragment of Complement Is Superior to Conventional C3 as a Diagnostic Biomarker in Systemic Lupus Erythematosus.

Authors:  Anne Troldborg; Lisbeth Jensen; Bent Deleuran; Kristian Stengaard-Pedersen; Steffen Thiel; Jens Christian Jensenius
Journal:  Front Immunol       Date:  2018-03-26       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.